Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Advancing Prostate Cancer Care

October 12th 2014

The prostate cancer team at the Comprehensive Cancer Center at Wake Forest Baptist Medical Center has recently focused on two primary areas: minimally invasive care and clinical research.

Dr. Antonarakis on AR-V7 and Resistance to AR-Targeting Agents in mCRPC

October 8th 2014

Emmanuel S. Antonarakis, MBBCh, assistant professor, Johns Hopkins Medicine, discusses AR-V7 and resistance to AR-targeting agents in men with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Fernandez Discusses Immunotherapy Plus Radiation Therapy for Prostate Cancer

October 6th 2014

Eduardo Fernandez, MD, PhD, FACRO, Senior Vice President, Medical Affairs / Medical Director for Latin America, Radiation Oncologist, 21st Century Oncology, discusses the potential for immunotherapy and radiation therapy to be used together to treat prostate cancer.

Hopkins Researcher Discusses AR-V7 and Resistance to AR-Targeting Agents

October 4th 2014

Androgen receptor splice variant-7 (AR-V7) is a truncated form of the AR that does not have the ligand-binding domain. Detection of AR-V7 in circulating tumor cells (CTCs) can be used to predict resistance to AR-targeting agents, such as abiraterone or enzalutamide.

Vogelzang Disputes 'Weak' Guideline Rating for Sipuleucel-T

October 3rd 2014

In a recent guideline for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC), the American Society of Clinical Oncology (ASCO) and Cancer Care Ontario (CCO) shared their thoughts on the implementation of six drugs approved since their previous recommendations were issued in 2007, as well as on older drugs.

New Data Provide Insight Into Optimal Pre-Chemo Treatments for mCRPC

September 30th 2014

The combination of abiraterone acetate and prednisone has demonstrated a statistically significant improvement in overall survival (OS) for men with metastatic castration-resistant prostate cancer (mCRPC) who had not received prior treatment with chemotherapy

Dr. Petrylak on the Results of the Phase II STRIDE Study

September 27th 2014

Daniel P. Petrylak, MD, Professor of Medicine (Medical Oncology) and of Urology, Professor and Co-Director, Signal Transduction Research Program, Yale Cancer Center, discusses results from the phase II STRIDE study.

Dr. Fitch Discusses Dose Escalation of Radiation in Prostate Cancer

September 26th 2014

Dwight L. Fitch, MD, Radiation Oncologist, 21st Century Oncology in Bradenton, Florida, discusses dose modifications for radiation therapy in patients with prostate cancer.

Infections After Prostate Biopsy Are On the Rise, Large Study Shows

September 25th 2014

The rate of severe urinary tract infections following transrectal ultrasound-guided biopsy for the detection of prostate cancer has been on the rise in Sweden

Link May Exist Between Baldness and Aggressive Prostate Cancer

September 24th 2014

If a man has a certain pattern of baldness when he reaches 45 years of age, he faces a 45% higher risk of developing aggressive prostate cancer later in life than does a man with no baldness at that age.

Changing Trends in Prostate Cancer Therapy: Is Earlier Better?

September 24th 2014

Although the incidence and mortality of prostate cancer remain formidable problems in the United States, clinicians have many new agents with proven overall survival (OS) benefits to recommend for patients with metastatic disease.

PREVAIL Trial Investigator Discusses Pre-Chemo Enzalutamide Indication

September 20th 2014

Last week, the FDA expanded the approval for enzalutamide (Xtandi) to include the treatment of men with chemotherapy-naive metastatic castration-resistant prostate cancer.

Robotic Prostatectomy Rises, and So Do Costs: Study Tracks Patterns

September 17th 2014

Robotic-assisted radical prostatectomy (RARP) was widely adopted in the United States between 2003 and 2010, mainly among high-volume surgeons.

Vessel-Sparing Radiation Preserves Sexual Function in Men With Prostate Cancer

September 16th 2014

With the use of MRI imaging to restrict doses to erectile tissues, nearly half of men treated with external beam radiation therapy (EBRT) for prostate cancer were able to be sexually active without aids or medications 5 years later, and nearly 80% could be sexually active if such support was an option

Abbreviated Course of ADT + Radiation Improves QoL in High-Risk Prostate Cancer

September 16th 2014

When given along with radiation therapy to men with high-risk prostate cancer, 18 months of androgen-deprivation therapy (ADT)-as opposed to a 36-month course-not only generates similar long-term outcomes, but results in a better quality of life

Dr. Hussain on the Importance of Multidisciplinary Care

September 12th 2014

Maha H. Hussain, MBChB, from the University of Michigan Comprehensive Cancer Center, explains that care should be multi- and interdisciplinary, in order to provide the best possible outcomes.

Beyond PSA: A Summary Review of Predictive/Prognostic Biomarkers in Prostate Cancer

September 11th 2014

Although prostate cancer (PC) is the most common solid tumor malignancy among men in the Western Hemisphere, disease-specific mortality remains low, primarily due to optimized screening, diagnosis, and treatment.

FDA Approves Pre-Chemo Enzalutamide for mCRPC

September 10th 2014

The FDA has expanded the approval for enzalutamide to include the treatment of men with chemotherapy-naive metastatic castration-resistant prostate cancer.

UCSF Researcher Puts Focus on AR Resistance Mechanisms

September 10th 2014

Terence Friedlander, MD, specializes in understanding the basic biology of genitourinary cancer, in particular cancer of the bladder and prostate, in developing new treatments and studying new ways to overcome treatment resistance.

A Call to Arms

September 8th 2014

The year was 1989, and I was one year away from finishing six years of residency in general surgery and urology.